In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin/Lilly: Resurrections and Conversions

Executive Summary

Resurrections are an old biotech story. Now it's Amylin's happy duty to play the leading role--thanks to a product surprise. Its best known product, Symlin, delayed in the clinic, looks to be a smaller market product for diabetes than AC2993, which could compete with oral medicines. Lilly's signed up for a major deal on the product when its own competitive program failed. The deal itself gets Amylin a true partner's interest in the development and commercial prospects for the drug, but includes some interesting convertibility features that put Amylin at some risk if it doesn't perform.
Advertisement

Related Content

BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
Bristol: Rebuilding a Diabetes Franchise--with Insulin
BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
Why Less Is More: The Hidden Cost of Complexity in Pharma Alliances
Why Less Is More: The Hidden Cost of Complexity in Pharma Alliances
Zealand Deals Diabetes Drug to Aventis
Lilly & Boehringer: When You Gotta Partner, You Gotta Partner
Biotech Layoffs Hit Hardest In Discovery
Biotech Layoffs Hit Hardest In Discovery
Amylin's Leap of Faith

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel